

AUG 16 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/786,810	
	Filing Date	February 25, 2004	
	First Named Inventor	Benavides, Jesus et al	
	Art Unit	1614	
	Examiner Name	Jones, Dwayne C.	
Total Number of Pages in This Submission	9 pgs.	Attorney Docket Number	ST01023 US CNT

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input checked="" type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	
	1. Petition And Amendment - 3 pgs.	
	2. Statement Pursuant to 37 C.F.R. § 1.48 (a) (1) - 2 pgs.	
	3. Statement Under 37 CFR 3.73(b) - 1 pg.	
	4. Executed Declaration - 2 pgs.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Balaram Gupta		
Date	August 16, 2005	Reg. No.	40,009

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 9 pgs.)			
Signature			
Typed or printed name	Maribel Mendez	Date	August 16, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
AUG 16 2005**PATENT**

Docket No.: ST01023-US-CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Benavides, Jesus et al.

Examiner: Jones, Dwayne C.

Serial No.: 10/786,810

Art Unit: 1614

Filed: February 25, 2004

Title: **Combination of a CB1 Receptor
Antagonist and of a Product which
Activates Dopaminergic
Neurotransmission in the Brain, the
Pharmaceutical Compositions
Comprising Them and Their Use in the
Treatment of Parkinson's Disease****TELEFAX CERTIFICATE**I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for Patents,
Alexandria, VA 22313, at (571) 273-8300 on8-16-05
Date of Transmission

Signature

PETITION AND AMENMDMENT PURSUANT TO 37 C.F.R. § 1.48(a)Mail Stop: Director, Group Art Unit 1600
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PETITION

Pursuant to Rule 48(a) there is an error in the names of the inventors in that the following named inventor was inadvertently entered twice:

HENIN (the fifth inventor in the declaration)

AMENDMENT

Pursuant to Rule 48(a)(1), please delete the above-named fifth inventor, HENIN, from all of the necessary USPTO papers (including the USPTO computer database) in the above noted patent application since this name was entered twice in error.

Application Ser. No.: 10/786,810
Filing Date: February 25, 2004
Examiner: Jones, Dwayne C.

Applicants further submit that the above noted error arose without any deceptive intention on the part of Mr. Yvette Henin who inadvertently entered his name twice while signing the declaration.

Also enclosed herewith is a statement as required under Rule 48(a)(2) from Mr. Yvette Henin, which sets forth the inadvertent error in entering his name twice, which occurred without deceptive intention on his part.

Pursuant to Rule 48(a)(3), a new declaration executed by the four named inventors is also enclosed herewith. It is respectfully submitted that this new declaration be entered into record and request that the one on file be deleted.

Please charge the required fee set forth in Rule 1.17(i) to our Deposit Account No. 18-1982.

Finally, also enclosed herewith is a Rule 3.73(b) statement from the assignee of record in concurrence of this submission as required under Rule 1.48(a)(5).

In view of the foregoing, it is submitted that the requirement of 37 C.F.R. § 1.48(a) have been satisfied and it is requested that this Petition be granted. Notification of receipt and entry of this Petition and Amendment are respectfully requested.

As note above, the Commissioner is hereby authorized to charge the fees involved due to this submission to Deposit Account No. 18-1982 for Aventis

ST01023-US-CNT

-2 of 3-

Application Ser. No.: 10/786,810
Filing Date: February 25, 2004
Examiner: Jones, Dwayne C.

Pharmaceuticals, Inc., Bridgewater, NJ. Please credit any overpayment to Deposit
Account No. 18-1982.

Respectfully submitted,

August 16, 2005



Balaram Gupta, Reg. No. 40,009
Attorney/Agent for Applicant

Encl: Statement from Mr. Yvette Henin
Rule 3.73(b) Statement form Assignee
New Executed Decalaration

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone: 908-231-3364
Telefax: 908-231-2626

RECEIVED
CENTRAL FAX CENTER

AUG 16 2005

PATENT

Docket No.: ST01023 US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Jesus Benavides, et al

Examiner: Jones, Dwayne C.

Art Unit: 1614

Serial No.: 10/786,810

Filed: February 25, 2004

Title: Combination of a CB1 Receptor Antagonist
and of a Product Which Activates
Dopaminergic Neurotransmission in the
Brain, the Pharmaceutical Compositions
Comprising Them and Their Use in the
Treatment of Parkinson's Disease

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at (571) 273-8300 on

Date of Transmission

Signature

Mail Stop: Director, Group Art Unit 1600
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

STATEMENT PURSUANT TO 37 C.F.R. § 1.48(a)(1)

Sir:

I, Yvette Henin, hereby state that:

1. I am named as the third of four inventors in the above-identified application.
2. As my residential address had recently changed, while signing the declaration in the above identified patent application, I crossed out my old address and handwrote my new address. At the same time, I inadvertently re-wrote my last name and the new address as a fifth inventor.
3. The above error in inventorship occurred without deceptive intention on my part.

ST01023 US CNT

-1 of 2-

Application Ser. No.: 10/786,810
Filing Date: February 25, 2004
Examiner: Jones, Dwayne C.

4. In view of the above noted inadvertent error, I request deletion of my name listed for the second time as the fifth inventor. However, I remain as the third inventor on this application.
5. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is desired.

By:

Yvette Henin

Yvette Henin
18, Cours du 7^{ème} Art
75019 Paris (France)

May 2nd 2005
Date